Updating results

115 results

Sort: Relevance | Date

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography

In development [GID-DG10034] Expected publication date: 30 September 2020

Diagnostics guidance In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

In development [GID-DG10023] Expected publication date: 27 May 2020

Diagnostics guidance In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: diagnostics consultation

We are listening to your views on this diagnostics guidance. Comments close 04 February 2020.

Diagnostics guidance In consultation

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 26 August 2020

Diagnostics guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Diagnostics guidance In development

KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Diagnostics guidance In development

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)

Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.

Diagnostics guidance Published December 2011

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)

This guideline has been updated and replaced by NICE guideline NG131.

Diagnostics guidance Published June 2015